Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?
Rebecca Vincent, David M. Williams, Marc Evans
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 12, pp. 2227-2240
Open Access | Times Cited: 18

Showing 18 citing articles:

Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
David M. Williams, Hannah Jones, Jeffrey W. Stephens
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 281-295
Open Access | Times Cited: 78
An update on peptide-based therapies for type 2 diabetes and obesity
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2023) Vol. 161, pp. 170939-170939
Open Access | Times Cited: 71
Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes
Richeek Pradhan, Hui Yin, Oriana Hoi Yun Yu, et al.
Diabetes Care (2022) Vol. 45, Iss. 4, pp. 819-829
Open Access | Times Cited: 41
One-Step Synthesis of Carbon Nanoparticles Capable of Long-Term Tracking Lipid Droplet for Real-Time Monitoring of Lipid Catabolism and Pharmacodynamic Evaluation of Lipid-Lowering Drugs
Meng-Xian Liu, Na Ding, Shuai Chen, et al.
Analytical Chemistry (2021) Vol. 93, Iss. 12, pp. 5284-5290
Closed Access | Times Cited: 42
Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: Role of cardiac redox signaling
Ioanna Andreadou, Andreas Daiber, Gary F. Baxter, et al.
Free Radical Biology and Medicine (2021) Vol. 166, pp. 33-52
Open Access | Times Cited: 39
Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review
Ran Lu, Ye Liu, Tianpei Hong
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. S1, pp. 13-26
Closed Access | Times Cited: 16
Taste and its receptors in human physiology: A comprehensive look
Chao Li, Yaxin Li, Qing Sun, et al.
Food Frontiers (2024) Vol. 5, Iss. 4, pp. 1512-1533
Open Access | Times Cited: 5
Demethylenetetrahydroberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice
Yuanqiang Zhang, Jing Wen, Dongqing Liu, et al.
Life Sciences (2021) Vol. 281, pp. 119778-119778
Closed Access | Times Cited: 27
Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?
David M. Williams, Michael Atkinson, Marc Evans
Stroke (2023) Vol. 54, Iss. 5, pp. 1441-1451
Closed Access | Times Cited: 7
Medicinal Perspective of 2,4‐Thiazolidinediones Derivatives: An Insight into Recent Advancements
Sneha Gupta, Sumeet Jha, Supriya Rani, et al.
ChemistryOpen (2024)
Open Access | Times Cited: 1
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
Alana Aragón‐Herrera, Manuel Otero-Santiago, Laura Anido‐Varela, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 6
Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
Masao Koike, Hitoki Saito, Genta Kohno, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11463-11463
Open Access | Times Cited: 7
Relevance of GLP-1 receptor agonists or SGLT-2 inhibitors on the recruitment for clinical studies in patients with NAFLD
Michael Holzhey, David Petroff, Kerstin Wirkner, et al.
European Journal of Gastroenterology & Hepatology (2023) Vol. 36, Iss. 1, pp. 107-112
Closed Access | Times Cited: 2
Clinico-pathological features and related risk factors of Type-2 diabetes mellitus complicated with nonalcoholic fatty liver
Lisha Chen, Li Jiang
Pakistan Journal of Medical Sciences (2022) Vol. 38, Iss. 7
Open Access | Times Cited: 4
The Bidirectional Relationship Between Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study
David M. Williams, A. Jmaa, Jake Cragg, et al.
Cureus (2024)
Open Access
Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential
Lucia Brodosi, Alessandra Musio, Francesca Alessandra Barbanti, et al.
Hepatoma Research (2020) Vol. 2020
Open Access | Times Cited: 2
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
I Dewa Nyoman Wibawa, I Ketut Mariadi, Gde Somayana, et al.
World Journal of Diabetes (2023) Vol. 14, Iss. 5, pp. 549-559
Open Access
Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?
David M. Williams, SK V. Krishnamoorthy, Chin Lye Ch’ng, et al.
Obesity (2022) Vol. 30, Iss. 5, pp. 969-970
Closed Access
Page 1

Scroll to top